You are here: Industry Insights > COV001

News List

Vaxzevria Induced Immunity for at Least One Year Following a Single Dose and Strong Immune Responses Following Either a Late Second Dose or a Third Dose drugs
July 08, 2021
A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose.
A Single Dose of Vaxzevria Induced Immunity for One Year, Second and Third Dose Increase Response americanpharmaceuticalreview
June 30, 2021
Oxford-led COV001 and COV002 trials showed that Vaxzevria induced a strong immune response following a long second dose interval (up to 45 weeks) and after a third booster dose.
COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial worldpharmanews
July 21, 2020
Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.